Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or
without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated
group will serve as controls for improved glycemic control, since the investigators have
shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM
patients.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio